NCT05070390View on ClinicalTrials.gov

A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions

Moderate Renal Impairment

Interventions

DRUG

Enlicitide Chloride

10 mg capsule administered orally

Trial Locations (2)

33009

Velocity Clinical Research, Hallandale Beach ( Site 0002), Hallandale

37920

Alliance for Multispecialty Research, LLC ( Site 0001), Knoxville

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT05070390 - A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007) | Biotech Hunter | Biotech Hunter